...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries
【24h】

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

机译：在四个国家中与新型蛋白D结合物肺炎球菌疫苗PHiD-CV相关的结果和费用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study estimated the impact of routine vaccination of infants with a new 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on health outcomes and costs across the entire population in Canada, Germany, Mexico, and Norway. A compartmental, static model with a 1-year time period for a steady-state population that allowed for the incorporation of direct and indirect (i.e., herd immunity and serotype replacement) vaccine effects across all age groups was used. Cases of disease prevented, deaths prevented, life-years gained, quality-adjusted life-years gained, and incremental costs in the steady-state year were calculated for PHiD-CV compared with 7-valent pneumococcal conjugate vaccine (PCV-7). A short-term analysis was also conducted to estimate the incremental difference in disease and cost outcomes for the two vaccines within the first 10 years. All costs were in 2008 local currency. In all four countries, the model estimated that PHiD-CV prevented more cases of disease, prevented more deaths, and resulted in more life-years and quality-adjusted life-years compared with PCV-7 in both the short term and the steady-state year. Assuming price parity for the vaccines, the model projected that routine vaccination with PHiD-CV resulted in lower costs compared with PCV-7 in both the short term and the steady-state year. Scenario analysis showed the incremental cost savings for PHiD-CV compared with PCV-7 in the steady-state year were sensitive to assumptions regarding duration of vaccine efficacy
机译：这项研究估计了加拿大，德国，墨西哥和挪威的整个人群的常规疫苗接种对新生儿的10价肺炎球菌不可分型流感嗜血杆菌蛋白D结合疫苗（PHiD-CV）的健康结果和费用的影响。使用了为期1年的稳态人口隔间静态模型，该模型允许在所有年龄段均纳入直接和间接（即牛群免疫力和血清型替代）疫苗效果。与7价肺炎球菌结合疫苗（PCV-7）相比，PHiD-CV可以计算出疾病预防，死亡预防，生命年限，质量调整生命年的增长以及稳态年的增量成本。还进行了短期分析，以估计在最初的10年中两种疫苗在疾病和成本结果方面的增量差异。所有费用均以2008年当地货币计算。该模型估计，在短期和稳定状态下，与PCV-7相比，PHiD-CV与PCV-7相比，预防了更多的疾病病例，避免了更多的死亡，并导致了更多的生命年和质量调整的生命年。州年。假设疫苗的价格均等，该模型预计在短期和稳态年份，与PCV-7相比，常规接种PHiD-CV疫苗可降低成本。方案分析表明，在稳态年份，与PCV-7相比，PHiD-CV节省的增量成本对疫苗有效期的假设敏感

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号